SCENT part 3. Acute effects on smellprints of chemotherapy in patients with lung cancer.

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 3. Acute effects on smellprints of chemotherapy in patients with lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON27548

Enrollment

Registered

2008-12-29

Start date

2009-01-02

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

electronic nose smell-print exhaled breath lung cancer chemotherapy

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent is obtained; 2. newly diagnosed adenocarcinoma or squamous cell carcinoma stage IIIA, IIIB or IV or small cell lung cancer); 3. adults 18-80 years; 4. scheduled for chemotherapy as first part of the treatment: Cisplatin/Gemcitabine (NSCLC) and Cisplatin/Etoposide (SCLC).

Exclusion criteria

Exclusion criteria: 1. Previous chemotherapy; 2. unable to evaluate response with the RECIST criteria; 3. unable to follow the instructions for the eNose measurement.

Design outcomes

Primary

Measure	Time frame
The primary objective is to investigate whether the eNose can discriminate the smellprints obtained before and after 1 cycle of chemotherapy in patients with specific histological types of lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma and SCLC).	—

Secondary

Measure	Time frame
The secondary objectives are: 1. To investigate whether the eNose can discriminate between the baseline smellprints of patients with different histological types of lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma and SCLC); 2. To investigate whether the pre-chemotherapy smellprint is related to: a. the stage of the disease according to the stage grouping of the Mountain classification (NSCLC) [21] or division into LD or ED (SCLC) [2]; b. metabolic activity of the disease as assessed by Standard Uptake Value (SUV) on PET-CT scan; 3. To investigate whether the potential change in smellprint after 1 cycle of chemotherapy is related to tumour response (determined after the second cycle of chemotherapy) according to the RECIST criteria.	—

Measure

Time frame

The secondary objectives are: 1. To investigate whether the eNose can discriminate between the baseline smellprints of patients with different histological types of lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma and SCLC); 2. To investigate whether the pre-chemotherapy smellprint is related to: a. the stage of the disease according to the stage grouping of the Mountain classification (NSCLC) [21] or division into LD or ED (SCLC) [2]; b. metabolic activity of the disease as assessed by Standard Uptake Value (SUV) on PET-CT scan; 3. To investigate whether the potential change in smellprint after 1 cycle of chemotherapy is related to tumour response (determined after the second cycle of chemotherapy) according to the RECIST criteria.

—

Contacts

Public ContactJ. Maten, van der

Dept. of pulmonary diseases MCL Leeuwarden

j.maten@znb.nl+31 (0)58 286 6190

Outcome results